Aetna, a CVS Health company, partners with leading digital addiction care provider Workit Health to provide services for its members in select states.
The National Institute on Drug Abuse contract advances Workit Health’s industry leading telemedicine addiction recovery program, promoting health equity through individualized support that solves for social determinants of health.
In new JAMA article, telemedicine for opioid use disorder such as Workit Health offers promising solution for rural counties hit hardest by the overdose crisis.
Workit Health, the nation’s premier provider of telehealth addiction treatment, announces today their LegitScript certification after an extensive review of the company’s treatment practices.
Workit Health, a telehealth addiction treatment company bringing affordable, evidence-backed care to individuals, healthcare organizations, and employers, today announced a Series A investment led by Blue Cross Blue Shield Venture Partners.
Workit Health’s online addiction treatment program meets the rigorous standards set by The Joint Commission and accepted by national healthcare experts.
The hybrid, online/offline addiction care company Workit Health is dedicated to rigorous standards of social impact performance, ethical and sustainable business practices, as well as accountability and transparency in addiction treatment solutions.
Workit Health and Ascension’s Brighton Center for Recovery announced an innovative clinical pilot partnership to provide patients with a seamless addiction care experience. The two industry-leading organizations are teaming up to provide a full spectrum of addiction care, including prevention, inpatient and outpatient treatment, aftercare, and recovery.
The White House Commission on Combating Drug Addiction’s interim report recommended the President declare a national public health emergency due to the opioid crisis. Lisa McLaughlin and Robin McIntosh, Co-CEOs of Workit Health, the world’s first online addiction care program, respond with the following statement.
This site uses cookies to improve your experience. By using this site, you consent to our use of cookies.